Genesis Therapeutics

Genesis Therapeutics is a next-generation molecular AI platform for accelerating small molecule drug discovery. The company uses cutting-edge 3D spatial graph modeling and molecular simulation to create novel drug candidates. The platform combines deep learning for property prediction and language models for molecular generation to develop high-potency and selective small molecule drugs that can target previously inaccessible and undruggable biological targets.

Genesis Therapeutics brings together the expertise of seasoned drug hunters, deep learning researchers and software engineers to pioneer AI in biochemistry. The company's platform, GEMS (Genesis Exploration of Molecular Space), combines Dynamic PotentialNet, the company's proprietary approach to predicting potency, selectivity and ADMET, with molecular simulation and molecular generation. This allows the company to predict 3D binding dynamics, including protein flexibility and critical water molecules.

Key components include:

• GEMS: The core platform that combines deep learning and molecular simulations for property prediction and language models for molecular generation.
• Dynamic PotentialNet: The company's proprietary technology for predicting potency, selectivity and ADMET properties using 3D spatial graphs and machine learning.
• Molecular Simulation: The company's proprietary platform for simulating 3D binding dynamics.
• Molecular Generation: The engine that generates novel molecules and explores chemical space for each drug program.

Genesis Therapeutics is focused on meeting critical patient needs, tackling breakthrough treatments for severe and devastating diseases. The company has secured funding from leading technology and biotech investors, including Andreessen Horowitz and Eli Lilly, to pursue its mission.

Genesis Therapeutics has already shown results through AI discovery deals with major partners and investments. That's a strong indication of the potential of AI-driven drug discovery to shake up the biotech industry, especially when it comes to hard-to-drug targets. By combining advanced AI technology with molecular simulations and experienced drug development, Genesis Therapeutics is working to speed the development of critical new medicines and help patients.

Published on June 14, 2024